Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pain relief showdown: one drug vs. two for facial nerve pain

NCT ID NCT07625410

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking gabapentin along with oxcarbazepine works better than oxcarbazepine alone for trigeminal neuralgia, a condition causing severe facial pain. 44 adults were split into two groups and had their pain measured over 2 months. The goal was to see which approach provides better pain relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oxcarbazepine and gabapentin
What this could lead to
If the combination works better, it could offer a more effective way to manage trigeminal neuralgia pain with existing drugs.
What could go wrong
This is a small, single-center study with only 44 patients and short follow-up. Results may not apply to everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

44 people

The number who actually took part.

Started

May 2023

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of either gender aged 20-80 years * Patients presenting to the Outpatient Department (OPD) * Patients fulfilling the diagnostic criteria for idiopathic trigeminal neuralgia according to the International Headache Society (IHS) Exclusion Criteria: * Patients with orofacial or odontogenic pain conditions other than trigeminal neuralgia (TN) * Patients with temporomandibular joint (TMJ) disorders * Patients with a centralized cause of TN evident on MRI * Patients unwilling to participate in the study * Patients who failed to attend follow-up visits * Pregnant or lactating females * Patients with a history of previous surgical procedures for neuralgia * Patients with known allergy to medications used for neuralgia * Patients with significant comorbid medical conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Effectiveness of drugs was compared for treating trigeminal neuralgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rehman College of Dentistry

    Peshawar, Khyber Pakhtunkhwa, 25100, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.